scholarly journals Laser photoablation of renal pelvic tumours

2013 ◽  
Vol 2 (4) ◽  
pp. 413 ◽  
Author(s):  
Bryce Weber ◽  
Theresa J. McCallum ◽  
John Tulip ◽  
Ronald B. Moore
Keyword(s):  
Renal Pelvis ◽  
Yttrium Aluminum Garnet ◽  
Transitional Cell ◽  
Previous History ◽  
Subsequent Treatment ◽  
Clinical Effects ◽  
Percutaneous Approach ◽  
Yag Laser ◽  
History Of ◽  
Pelvic Urine

We evaluated the clinical effects of the Zeiss OPMILAS (Oberkochen, Germany) multi–yttrium–aluminum–garnet (YAG) laser in the treatment of renal pelvic tumours as an alternative to nephroureterectomy. Four patients with evidence of transitional cell carcinoma (TCC) in the renal pelvis and a previous history of TCC of the bladder or opposite renal pelvis were treated with the Zeiss OPMILASmulti-YAG laser. Three patients underwent a retrograde ureteroscopic approach and 1 patient required percutaneous resection. Two wave lengths were used:1060 nm continuous coagulative mode and 1440 nm pulsed ablative mode. The patients were followed for 12, 24, 76 and 84 months, respectively. Two patients showed no evidence of recurrence as determined by cystoscopy, retrograde pyelography and selective pelvic urine cytology. One patient experienced a recurrence of TCC requiring subsequent treatment. The ureteroscopic approach was associated with fewer complications and a more rapid recovery, compared with the percutaneous approach. All patients with solitary kidneys avoided dialysis.

405: Previous History of Bladder Cancer is an Independent Prognostic Factor for Upper Tract Transitional Cell Carcinoma

2007 ◽  
Vol 177 (4S) ◽  
pp. 135-135
Author(s):  
Eiji Kikuchi ◽  
Akira Miyajima ◽  
Ken Nakagawa ◽  
Mototsugu Oya ◽  
Takashi Ohigashi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Factor ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Previous History ◽  
Independent Prognostic Factor ◽  
Upper Tract ◽  
History Of

Microcystic Transitional Cell Carcinoma

2002 ◽  
Vol 126 (7) ◽  
pp. 859-861 ◽  
Author(s):  
Xavier Leroy ◽  
Emmanuelle Leteurtre ◽  
Alexandre De La Taille ◽  
David Augusto ◽  
Jacques Biserte ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Renal Pelvis ◽  
Transitional Cell ◽  
Macroscopic Hematuria ◽  
Computed Tomographic ◽  
First Case ◽  
History Of ◽  
Invasive Transitional Cell Carcinoma

Abstract Microcystic transitional cell carcinoma is a rare variant of urothelial carcinoma; to date, it has been described only in the urinary bladder. We report 2 cases of microcystic transitional cell carcinoma arising in the renal pelvis. The first case occurred in a 73-year-old man with a history of superficially invasive transitional cell carcinoma who presented with macroscopic hematuria and anemia. The second case occurred in a 62-year-old woman who had no relevant medical history and presented with hematuria. Computed tomographic scan revealed a tumor of the renal pelvis. In both cases, microscopic examination showed invasive transitional cell carcinoma with prominent cystic features. The cysts were irregular in size and were deeply infiltrative. The cysts were lined by single or multiple layers of cuboidal or flattened cells with minimal cytological atypia. The first patient died of his disease 18 months after presentation. The second patient remained well at her 6-month follow-up examination. Microcystic transitional cell carcinoma is an unusual, deceptively bland variant of urothelial carcinoma, which can mimic benign lesions.

Transitional-Cell Carcinoma of the Renal Pelvis: Ureteroscopic and Percutaneous Approach

2001 ◽  
Vol 15 (4) ◽  
pp. 377-383 ◽  
Author(s):  
Evangelos N. Liatsikos ◽  
Caner Z. Dinlenc ◽  
Rakesh Kapoor ◽  
Arthur D. Smith
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Pelvis ◽  
Transitional Cell ◽  
Percutaneous Approach

Applications of transcranial direct current stimulation in children and pediatrics

2017 ◽  
Vol 28 (2) ◽  
pp. 173-184 ◽  
Author(s):  
Guadalupe Nathzidy Rivera-Urbina ◽  
Michael A. Nitsche ◽  
Carmelo M. Vicario ◽  
Andrés Molero-Chamizo
Keyword(s):  
Direct Current ◽  
Transcranial Direct Current Stimulation ◽  
Developmental Disorders ◽  
Cortical Excitability ◽  
Previous History ◽  
Therapeutic Effects ◽  
Clinical Effects ◽  
Direct Current Stimulation ◽  
Brain Functions ◽  
History Of

AbstractTranscranial direct current stimulation (tDCS) is a neuromodulatory noninvasive brain stimulation tool with potential to increase or reduce regional and remote cortical excitability. Numerous studies have shown the ability of this technique to induce neuroplasticity and to modulate cognition and behavior in adults. Clinical studies have also demonstrated the ability of tDCS to induce therapeutic effects in several central nervous system disorders. However, knowledge about its ability to modulate brain functions in children or induce clinical improvements in pediatrics is limited. The objective of this review is to describe relevant data of some recent studies that may help to understand the potential of this technique in children with specific regard to effective and safe treatment of different developmental disorders in pediatrics. Overall, the results show that standard protocols of tDCS are well tolerated by children and have promising clinical effects. Nevertheless, treatment effects seem to be partially heterogeneous, and a case of a seizure in a child with previous history of infantile spasms and diagnosed epilepsy treated with tDCS for spasticity was reported. Further research is needed to determine safety criteria for tDCS use in children and to elucidate the particular neurophysiological changes induced by this neuromodulatory technique when it is applied in the developing brain.

Successful Treatment of Bouveret Syndrome Using Holmium: YAG Laser Lithotripsy

2005 ◽  
Vol 71 (10) ◽  
pp. 882-885 ◽  
Author(s):  
Evan B. Goldstein ◽  
Richard H. Savel ◽  
H. Leon Pachter ◽  
Jonathan Cohen ◽  
Peter Shamamian
Keyword(s):  
Yttrium Aluminum Garnet ◽  
Gallstone Ileus ◽  
Gallstone Disease ◽  
Outlet Obstruction ◽  
Abdominal Distension ◽  
Upper Esophageal Sphincter ◽  
Laser Lithotripsy ◽  
Yag Laser ◽  
History Of ◽  
Successful Removal

Although gallstone disease is highly prevalent, cholelithiasis causing gallstone ileus is uncommon. Consideration has been given for nonoperative strategies to resolve obstruction due to the significant age and comorbidities afflicting this population. A 94-year-old man presented with a 5-day history of abdominal distension and tenderness. CT scan revealed multiple large gallstones within the gallbladder, pneumobilia, and two ectopic gallstones (antrum of the stomach and distal ileum). The patient was taken to the operating room where an enterolithotomy and gastrotomy was performed with removal of gallstones and subsequent relief of obstruction. During the postoperative course, the patient developed symptoms of gastric outlet obstruction and underwent gastrointestinal endoscopy for diagnosis and treatment. Two large gallstones, present in the duodenum, were retracted into the stomach using a Roth net but could not be retrieved beyond the upper esophageal sphincter. A holmium: yttrium-aluminum-garnet (Holmium: YAG) laser was used for fragmentation of the stones, with subsequent successful removal. This is the first documented successful use of the holmium: YAG laser for the treatment of recurrent gallstone ileus. Physicians should remember that in a small but important subgroup of patients, endoscopy accompanied by laser lithotripsy may prove beneficial.

A Contemporary Clinicopathologic Analysis of Primary Urothelial Carcinoma of the Urethra Without Concurrent Renal Pelvic, Ureteral, or Bladder Carcinoma

2021 ◽  
pp. 106689692110324
Author(s):  
Fengming Chen ◽  
Shreyas Joshi ◽  
Bradley C. Carthon ◽  
Adeboye O. Osunkoya
Keyword(s):  
Urothelial Carcinoma ◽  
Renal Pelvis ◽  
Previous History ◽  
Low Grade ◽  
High Grade ◽  
Divergent Differentiation ◽  
History Of ◽  
Variant Histology

Primary urothelial carcinoma (UCa) of the urethra is relatively uncommon, and the underlying pathogenesis has not been well characterized, especially in the absence of concurrent UCa at other sites. A search for cases of primary UCa of the urethra was conducted. Patients with concurrent UCa of the renal pelvis, ureter, or bladder at the time of diagnosis of the primary tumor were excluded. Clinicopathologic and follow-up data were obtained. A total of 35 cases from 30 patients (27 male and 3 female) were included in the study. The mean patient age at the initial diagnosis was 71 years (range: 41-90 years). Cases were composed of high-grade UCa (26 of 35 = 74%), low-grade UCa (4 of 35 = 11%), and UCa in situ (5 of 35 = 14%). Invasion was present in 14 of 26 (54%) cases of high-grade UCa. Interestingly, 23 of 30 (77%) patients had a previous history of UCa including 7 (30%) cases with divergent differentiation or variant histology. Follow-up data were available in 23 patients with a mean duration of 26.7 months (range: 0.6-87 months). Eleven patients (31%) died of metastatic UCa. This is one of the largest studies to date of primary UCa of the urethra without concurrent UCa of the renal pelvis, ureter, or bladder. Previous history of UCa of the bladder, especially with divergent differentiation or variant histology is conceivably a key risk factor for developing subsequent primary UCa of the urethra. These findings are important for the development of surveillance protocols and therapeutic strategies.

Urinary NMP22 in the management of superficial bladder tumours after transurethral resection

1998 ◽  
Vol 65 (1) ◽  
pp. 74-76
Author(s):  
V. Serretta ◽  
P. Vasile ◽  
V. Falletta ◽  
A. Licata ◽  
S. Pomara ◽  
...  
Keyword(s):  
Transurethral Resection ◽  
Superficial Bladder Cancer ◽  
Transitional Cell ◽  
False Negative ◽  
Previous History ◽  
False Negative Rate ◽  
History Of ◽  
The Mean ◽  
Carcinoma Of The Bladder ◽  
Bladder Tumours

The aim of this study was to evaluate the clinical utility of the NMP22 test after transurethral resection of superficial transitional cell carcinoma of the bladder. The test was performed in 28 patients with histologically confirmed bladder tumours and in 41 patients who already had two consecutive negative cytological and cystoscopic results at least 3 months after TUR. In the first group the mean NMP22 value was 62.5 u/ml with a false negative rate of 18%. The specificity of the NMP22 test in 41 patients with a previous history of TCCB was 49%. No difference was detected between patients treated or not with intravesical chemotherapy. Despite its good sensitivity, the NMP22 test cannot be adopted as a routine tool in post-TUR surveillance of patients with superficial bladder cancer, due to its low specificity.

scholarly journals Clinical effects from household insecticide: pyrethroid or organophosphate toxicity?

2019 ◽  
Vol 12 (11) ◽  
pp. e230966
Author(s):  
Zahir Basrai ◽  
Cynthia Koh ◽  
Manuel Celedon ◽  
Jonathan Warren
Keyword(s):  
Emergency Room ◽  
Clinical Presentation ◽  
Acute Onset ◽  
Subsequent Treatment ◽  
Burning Sensation ◽  
Clinical Effects ◽  
Limited Data ◽  
History Of ◽  
Low Threshold ◽  
Organophosphate Toxicity

A 54-year-old man with a history of schizophrenia presented to the emergency room for weakness with associated lacrimosis, drooling, nausea, emesis, diarrhoea, diplopia and burning sensation on his skin that began 6 hours after spraying five cans of Raid on his carpet. He was noted to have miotic pupils and hyperactive bowel sounds. Given the clinical presentation, the patient was diagnosed with organophosphate (OP) toxicity. After being admitted, he developed symptoms associated with his OP toxicity and was successfully treated with atropine and pralidoxime. Most Raid products contain pyrethroids; however, both OPs and pyrethroids are available in commercial pesticides and patients may misidentify ingestions. There are limited data reporting the toxicity of pyrethroid overdose in humans and to guide its subsequent treatment. It is crucial to keep a low threshold for diagnosing and treating patients with acute onset of symptoms suspicious for an OP or pyrethroid toxidrome.

Sign in / Sign up

Export Citation Format

Share Document